Search PubMed⌕ Search

Biomedical subjects

K R Lees

Publications and source records attributed to K R Lees.

At least 91 records · Page 5Linked to original sources

Mistyping of the human angiotensin-converting enzyme gene polymorphism: frequency, causes and possible methods to avoid errors in typing.

A polymorphism of the gene encoding the human angiotensin I-converting enzyme (ACE), which is defined by an insertion/deletion polymorphism in intron 16, has been identified as a candidate genetic locus in the development of cardiovascular and renal disease. We have demonstrated that the accuracy of ACE genotyping is critically dependent on the strategy of the PCR used in typing. Of 1238 individuals genotyped by a standard method, 335 were typed as DD, 645 as DI and 258 as II. However, when DD individuals were retyped using modified methods (including either 5% dimethyl sulphoxide, or a 'hot start') 35 of the original 335 samples (10.5%) were retyped as DI. In approximately half of these mistyped samples, PCR amplification was assessed as inefficient by the absence of a third faint heteroduplex band in a control ID sample: when the assay was repeated without any modifications, the mistyped samples were correctly genotyped. In the remainder, mistyping persisted. In these cases, the use of a third 'nested' PCR primer specific for the I allele was required for successful genotyping, providing a more reliable strategy without the need for further modification to the PCR technique. Our results suggest that the triple primer approach is the method of choice for accurate ACE genotyping.

Dimethyl Sulfoxide↗

Detection of microemboli by transcranial Doppler ultrasound.

Doppler ultrasound detection of abnormally high-pitched signals within the arterial waveform offers a new method for diagnosis, and potentially for prediction, of embolic complications in at-risk patients. The nature of Doppler "microembolic" signals is of particular interest in patients with prosthetic heart valves, where a high prevalence of these signals is observed. Monitoring the middle cerebral artery with 2-MHz transcranial Doppler ultrasound (TC-2000, Nicolet Biomedical; Warwick, UK), we looked for microemboli signals in 150 patients (95 women and 55 men), and found 1 or more signals during a 30-min recording in 89% of 70 patients with Bjork-Shiley valves (principally monostrut), 54% of 50 patients with Medtronic-Hall valves, and 50% of 30 patients with Carpentier-Edwards valves (p < 0.001, chi 2). In the patients with Bjork-Shiley valves, the mean number of signals per hour was 59 (range, 42-86; 95% confidence interval), which was significantly higher than the mean in patients with Medtronic-Hall and Carpentier-Edwards valves (1.5[range, 0.5-2.5] and 1 [range, 0-5.3], respectively; both p < 0.04, multiple comparisons. Bonferroni correction). In the patients undergoing serial pre- and postoperative studies, the causative role of the valve implant was emphasized. There was no correlation between the number of emboli signals and a prior history of neurologic deficit, cardiac rhythm, previous cardiac surgery, or the intensity of oral anticoagulation, in patients with prosthetic heart valves. In Bjork-Shiley patients, dual (mitral and aortic) valves were associated with more signals than were single valves. In Medtronic-Hall patients, the signal count was greater for valves in the aortic position than it was for valves in the mitral position. Comparative studies of Doppler emboli signals in other clinical settings suggest a difference in composition or size of the underlying maternal between prosthetic valve patients and patients with carotid stenosis. These studies also suggest that the signals are of gaseous origin in valve patients. The clinical significance of continuing microembolism remains to be determined.

Carotid Stenosis↗

Blood pressure control after acute stroke.

BACKGROUND: Although long-term blood pressure control is known to prevent stroke, acute blood pressure reduction after stroke is associated with worse neurological and functional outcome. VASOACTIVE DRUG TREATMENT AFTER STROKE: Chronic blood pressure reduction for secondary prevention of stroke is presently being tested within the PROGRESS trial. This study uses angiotensin-converting enzyme (ACE) inhibitor-based treatment (perindopril) versus placebo. ACE inhibitors may reduce blood pressure without adversely affecting cerebral blood flow. We have recently reported elsewhere that perindopril 4 mg once daily, initiated within 2-7 days of acute ischaemic stroke, reduces blood pressure without adverse effects on cerebral blood flow as measured by Doppler ultrasound. Nevertheless, the optimal policy with regard to blood pressure management in the first 48 h after acute stroke remains uncertain. CONCLUSIONS: A clinical trial is proposed to establish whether it is better to maintain pre-existing antihypertensive therapy or to discontinue this temporarily.

Acute Disease↗

Clinical pharmacology of CNS 1102 in volunteers.

The high affinity noncompetitive N-methyl-D-aspartate receptor antagonist CNS 1102 (aptiganel hydrochloride, Cambridge NeuroScience, Cambridge, MA.) is neuroprotective in preclinical models of stroke when administered as pretreatment or up to 60 minutes postischemia, and has potential for treatment of acute stroke or traumatic brain injury in man. A total of 55 healthy male subjects have participated in three separate studies to determine the clinical pharmacology of CNS 1102, 43 of whom have received CNS 1102 in doses of up to 100 micrograms/kg. Administration of CNS 1102 has been studied as a 15-minute intravenous infusion, as a 15-minute loading intravenous infusion followed by a 4-hour maintenance infusion, or as a fixed-dose intravenous bolus over 90 seconds. CNS 1102 in normal volunteers is well tolerated in total doses up to 32 micrograms/kg whether as a bolus injection, 15-minute infusion or 4-hour infusion. Central nervous system affects are evident within minutes of administration, implying rapid drug penetration. CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours. Adjustment of doses by subject weight does not improve variability of these parameters, and fixed doses may thus be administered. CNS 1102 causes dose-dependent elevation of blood pressure, accompanied by clinical evidence of vasoconstriction. Global cerebral blood flow is maintained, whilst middle cerebral artery flow velocity increases. Symptoms of light-headedness, disorientation and paresthesia progress through euphoria, disinhibition, and hallucinations to psychomotor retardation, paranoia and catatonia as total administered dose increases.

Adult↗

Comparison of mean cerebral transit time and single-photon emission tomography for estimation of stroke outcome.

Mean cerebral transit time (MCTT) scanning is a possible alternative to cerebral single-photon emission tomography (SPET) for early assessment of cerebral perfusion after acute ischaemic stroke. Although MCTT is rapid, inexpensive and does not require sophisticated equipment, the relationship between MCTT and functional outcome is unknown. This study aimed to compare the effectiveness of SPET and MCTT in the prediction of functional outcome. Sixty-three patients undergoing cerebral computed tomography (CT), technetium-99m MCTT, and technetium-99m-labelled hexamethylpropylene amine oxime SPET soon after acute ischaemic stroke had outcome assessed after 3 months. Cerebral CT, SPET and MCTT scans were interpreted without reference to the clinical data; a single independent observer assessed outcome using the Barthel Index. The 3-month Barthel score in survivors was significantly correlated with volume of lesion on SPET (Spearman's r=-0.425, P<0.005) and with the ratio of mean affected hemisphere transit times to mean unaffected hemisphere transit times (Spearmen's r=-0.356, P <0.01), but not with CT lesion volume (Spearman's r = -0.175, P >0.1). Stepwise logistic regression identified volume of lesion on SPET as the only significant predictor of good functional outcome (Barthel score>70). The overall predictive accuracy was 73%. It is concluded that MCTT, although significantly correlated with functional outcome, failed to predict good functional recovery in individual stroke survivors. Since SPET provides more detailed localisation of perfusion deficits, and since SPET lesion volume can be used to predict functional outcome, SPET remains preferable to MCTT when perfusion imaging is required.

Aged↗

Diagnosis and therapeutic aspects of stroke.

Detailed assessment of stroke is essential to distinguish haemorrhage from infarction, to establish the vascular territory affected and to identify patients with carotid stenosis or cardio-embolic disease. Computed tomography scanning should be routinely undertaken. Duplex Doppler sonography and echocardiography should be readily available but used selectively. Hypertension should not be treated early after ischaemic stroke. Issues requiring research include the optimal time to institute treatment, the degree to which blood pressure should be lowered in the presence of carotid stenosis and the value of antihypertensive treatment in normotensive survivors of stroke. Anticoagulation should be more widely applied in the prevention of stroke in patients with atrial fibrillation. Thrombolysis for acute ischaemic stroke has potential benefits and risks. It should be used only within randomised clinical trials, some of which may soon report. Endogenous glutamate causes excitotoxic damage after cerebral ischaemia. Many pharmacological approaches to restrict neuronal loss within the ischaemic penumbra are now in clinical trials. Physicians managing hypertension should take a lead in researching blood pressure management and neuroprotective strategies after acute stroke, and in directing other preventive measures such as anticoagulation for atrial fibrillation.

Cerebrovascular Disorders↗

A body-worn gait analysis system for evaluating hemiplegic gait.

This paper describes a system for measuring the temporal parameters of hemiplegic gait. This system uses shoe insoles with sensors, acting as switches, placed under the heel, head of the first metatarsal, head of the fifth metatarsal and the big toe. This system is able to monitor gait for up to 10 min and can be used by the patient over any surface. Parameters for evaluating hemiplegic gait are defined, including scuffing during swing and the degree of inversion during stance.

Cerebrovascular Disorders↗

Systemic and cerebral hemodynamic responses to the noncompetitive N-methyl-D-aspartate (NMDA) antagonist CNS 1102.

The excitatory amino acid antagonists are being developed as neuroprotective drugs aimed at limiting ischemic neuronal damage. Their hemodynamic and neurologic side effects are important in assessing safety and tolerability. We studied CNS 1102, a high-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor-channel antagonist, in normal volunteers. The effects of 2 mg CNS 1102 were assessed in a single-blind, placebo-controlled, fixed-dose, cross-over trial comparing administration by intravenous infusion for 15 min or bolus for 2 min in 8 healthy male subjects. Cerebral hemodynamics were studied with carotid and vertebral duplex ultrasound imaging, common carotid artery walltracking, and middle cerebral artery velocity readings. CNS 1102 administration was associated with light-headedness, mild disorientation, perioral and peripheral paresthesias, and flushing. Mean arterial blood pressure (MAP) increased significantly from baseline 1 h after CNS 1102 administration, with a maximal increase of 17 mm Hg over placebo. Pulse rate was unchanged. Common carotid artery pulsatility decreased by 38.4% [8.3-64.5, 95% confidence interval (CI)] and vertebral pulsatility by 43.8% [11.5-74.1], both p < 0.02. No significant differences were detected for other velocity and flow parameters. Middle cerebral artery mean velocity increased by 4.6 cm/s (1.6-7.8 cm/s) and diastolic velocity by 4.6 cm/s (2.4-7.3 cm/s) (both p < 0.01), but systolic velocity was unchanged. The middle cerebral pulsatility index decreased by 11% (3.8-16.1), p < 0.001. CNS 1102 is well tolerated at a fixed dose of 2 mg in normal volunteers. Cerebral arteriolar constriction is inferred from the ultrasound results.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Ultrasonic evaluation of movement of the diaphragm after acute cerebral infarction.

Respiratory dysfunction is an important complication of acute stroke but its mechanisms are poorly understood. Previous indirect assessments suggest that paralysis of the diaphragm occurs contralateral to the cerebral lesion. Diaphragmatic excursion was studied with real time ultrasound during quiet and deep breathing in 50 patients within 72 hours of acute stroke and 40 controls. During quiet breathing, hemidiaphragmatic movements were not significantly different between right hemispheric stroke, left hemispheric stroke, and controls. During deep inspiration, there was a significant bilateral reduction in hemi-diaphragmatic excursion in patients with stroke, for both right hemispheric stroke and left hemispheric stroke when compared with controls (both P < 0.001). Thus isolated hemidiaphragmatic paresis does not occur but maximal excursion of the diaphragm is reduced bilaterally in patients with acute stroke. This is a likely contributor to the respiratory dysfunction after acute stroke.

Acute Disease↗

Clinical experience with excitatory amino acid antagonist drugs.

BACKGROUND: Excitotoxic damage due to excess release of neuronal glutamate is hypothesized to play a pivotal role in the pathogenesis of focal cerebral ischemia. Drugs that antagonize excitatory amino acid function are consistently neuroprotective in preclinical models of stroke, and many are now entering clinical trials. SUMMARY: Antagonists of the N-methyl-D-aspartate (NMDA) receptor are furthest advanced in clinical development for stroke. Both noncompetitive (aptiganel hydrochloride, dextrorphan) and competitive (selfotel, d-CPPene) antagonists have undergone tolerability studies in acute stroke and traumatic brain injury. These agents all cause a similar spectrum of neuropsychological symptoms, and several have important cardiovascular effects. Other modulatory sites on the NMDA receptor complex, notably the polyamine and magnesium ion sites, are also the subject of clinical trials. Glycine site antagonists are in early clinical development. Non-NMDA glutamate receptor antagonists remain in preclinical study. Neuroprotection by agents that block glutamate release in vitro may be due to sodium channel blockade in vivo, but some agents (619C89) exhibit neurological effects similar to NMDA antagonists in stroke. The therapeutic index is unknown for different drugs but may be determined by cardiovascular effects, especially hypotension, which may be detrimental after stroke. CONCLUSIONS: Excitatory amino acid antagonists are in advanced development in the treatment of stroke and traumatic brain injury. A similar pattern of side effects is apparent with the majority of agents. However, cardiovascular effects may ultimately define therapeutic index for each drug.

Brain Ischemia↗

A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke.

BACKGROUND AND PURPOSE: Magnesium ions act as endogenous vasodilators of the cerebral circulation and act pharmacologically as noncompetitive antagonists of the N-methyl-D-aspartate receptor by virtue of their role as endogenous voltage-sensitive blockers of the ion channel. The preclinical efficacy of magnesium has been demonstrated in standard models of stroke. METHODS: Sixty patients were randomized to magnesium sulfate (8 mmol IV over 15 minutes and 65 mmol over 24 hours) or placebo within 12 hours of clinically diagnosed middle cerebral artery stroke. Pulse, blood pressure, and serum magnesium levels were monitored. Primary outcome was death or significant functional impairment (Barthel Index score < 60) at 3 months. RESULTS: Magnesium was well tolerated, with no significant adverse effects and no change in blood pressure or pulse rate. Laboratory and electrocardiographic variables did not differ significantly between placebo- and magnesium-treated groups. Serum magnesium rose from 0.76 mmol/L to 1.42 mmol/L over 24 hours and remained significantly higher than in the placebo group at 48 hours. Thirty percent of magnesium-treated and 40% of placebo-treated patients were dead or disabled (Barthel Index score < 60) at 3 months (P = .42). There was a decrease in the number of early deaths in the magnesium-treated group (P = .066, log-rank test). CONCLUSIONS: Magnesium sulfate is well tolerated after acute stroke and has no deleterious hemodynamic effects at this dose. Further trials are required to determine efficacy.

Acute Disease↗